Streamlining lung cancer diagnosis through genomic testing of cytology smears

Royal Brisbane and Womens Hospital0 个研究点目标入组 140 人开始时间: 2018年7月31日最近更新: 2020年3月16日

适应症

试验速览

暂无简介。

•Patients with enlarged mediastinal and/ or hilar lymph nodes suggestive of lung cancer requiring EBUS TBNA for tissue diagnosis.

•Patients deemed not suitable for bronchoscopy by their treating clinician
•Patients deemed unfit for bronchoscopy on the basis of
•Severe respiratory insufficiency or hypoxia, moderate-to-severe hypoxemia or any degree of hypercarbia
•Continuous use of anticoagulants (eg, heparin, warfarin) ADP-Receptor inhibitors (Clopidogrel), GP-IIB/IIIA- inhibitors (Abciximac), fish oil, etc) which cannot be discontinued.
•Uncorrectable coagulopathy or bleeding diathesis
•Platelet dysfunction or platelet count <100×10
•History of major bleeding with bronchoscopy
•Partial tracheal obstruction or obstruction of the superior vena cava
•Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy

发起方

Royal Brisbane and Womens Hospital